TY - JOUR
T1 - Relevance of age on survival of 341 patients with multiple myeloma treated with conventional chemotherapy
T2 - Updated results of the MM87 prospective randomized protocol
AU - Riccardi, A.
AU - Mora, O.
AU - Brugnatelli, S.
AU - Tinelli, C.
AU - Spanedda, R.
AU - De Paoli, A.
AU - Barbarano, L.
AU - Di Stasi, M.
AU - Bergonzi, C.
AU - Giordano, M.
AU - Delfini, C.
AU - Nicoletti, G.
AU - Rinaldi, E.
AU - Piccinini, L.
AU - Valentini, D.
AU - Ascari, E.
PY - 1998
Y1 - 1998
N2 - Age could influence the prognosis of multiple myeloma patients treated with conventional chemotherapy. Between January 1987 and March 1990, 341 consecutive previously untreated patients with multiple myeloma received chemotherapy within the prospective, multicentre, randomized Protocol MM87. Survival was evaluated in patients aged > or ≤ 66 years (the median age for the whole series) and in a subgroup of patients aged <55 years. These groups were similar for main clinical characteristics, including results of cytostatic treatment. As of May 1996, 271 (79%) of the 341 patients had died, and median follow-up of the 70 (21%) living patients was 82 months. Overall, younger patients survived longer than older ones. In fact, in patients > and ≤ 66 years, median survival was 31 and 44 months (P <0.00095) and the percentage of patients surviving over 72 months was 17% and 32% (P = 0.0018) respectively; in patients <55 years, these figures were 57 months and 35% respectively (P = 0.02 and 0.01, with respect to patients aged ≤ 55 years). In all groups, about 50% of the patients surviving over 72 months had stage I disease. For multiple myeloma patients treated with chemotherapy, survival is favourably affected by relatively young age and early stage of disease.
AB - Age could influence the prognosis of multiple myeloma patients treated with conventional chemotherapy. Between January 1987 and March 1990, 341 consecutive previously untreated patients with multiple myeloma received chemotherapy within the prospective, multicentre, randomized Protocol MM87. Survival was evaluated in patients aged > or ≤ 66 years (the median age for the whole series) and in a subgroup of patients aged <55 years. These groups were similar for main clinical characteristics, including results of cytostatic treatment. As of May 1996, 271 (79%) of the 341 patients had died, and median follow-up of the 70 (21%) living patients was 82 months. Overall, younger patients survived longer than older ones. In fact, in patients > and ≤ 66 years, median survival was 31 and 44 months (P <0.00095) and the percentage of patients surviving over 72 months was 17% and 32% (P = 0.0018) respectively; in patients <55 years, these figures were 57 months and 35% respectively (P = 0.02 and 0.01, with respect to patients aged ≤ 55 years). In all groups, about 50% of the patients surviving over 72 months had stage I disease. For multiple myeloma patients treated with chemotherapy, survival is favourably affected by relatively young age and early stage of disease.
KW - Age
KW - Bone marrow transplantation
KW - Conventional therapy
KW - Multiple myeloma
KW - Prognosis
KW - Survival
UR - http://www.scopus.com/inward/record.url?scp=15444352201&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=15444352201&partnerID=8YFLogxK
M3 - Article
C2 - 9472648
AN - SCOPUS:15444352201
VL - 77
SP - 485
EP - 491
JO - British Journal of Cancer
JF - British Journal of Cancer
SN - 0007-0920
IS - 3
ER -